Cart
sales@molnova.com
SLV319
CAS No. 362519-49-1
SLV319( (±)-SLV319 | (±)-BMS6462 )
Catalog No. M18476 CAS No. 362519-49-1
SLV319 has been used in trials studying the treatment of Obesity and Obesity and Type 2 Diabetes.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 40 | In Stock |
|
| 5MG | 65 | In Stock |
|
| 10MG | 125 | In Stock |
|
| 25MG | 250 | In Stock |
|
| 50MG | 462 | In Stock |
|
| 100MG | 669 | In Stock |
|
| 500MG | 1341 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSLV319
-
NoteResearch use only, not for human use.
-
Brief DescriptionSLV319 has been used in trials studying the treatment of Obesity and Obesity and Type 2 Diabetes.
-
DescriptionSLV319 has been used in trials studying the treatment of Obesity and Obesity and Type 2 Diabetes.(In Vitro):Cannabinoid receptor 1 (CB1R) antagonists appear to be promising drugs for the treatment of obesity, however, serious side effects have hampered their clinical application. Ibipinabant is a new, potent [Ki (CB1)=7.8 nM] and selective [Ki (CB2)=7.943 nM] CB1 antagonist [pA2 for arachidonic acid release in CHO cells=9.9] with in vitro pharmacological characteristics similar to rimonabant including inverse agonism and brain penetrance.(In Vivo):(±)-Ibipinabant ((±)-SLV319) (3 mg/kg) reduces unfasted glucose to a significantly greater degree than rimonabant at the same dose on days 17, 28 and 38. Chronic treatment with (±)-Ibipinabant ((±)-SLV319) significantly attenuates the progression of diabetes in ZDF rats, blunting the increase in blood glucose and HbA1c over time. Ibipinabant also reduces the hyperinsulinemia apparent at 6-8 weeks of age and attenuates the dramatic reduction in insulin levels observed 1-2 weeks later.
-
In VitroCannabinoid receptor 1 (CB1R) antagonists appear to be promising drugs for the treatment of obesity, however, serious side effects have hampered their clinical application. Ibipinabant is a new, potent [Ki (CB1)=7.8 nM] and selective [Ki (CB2)=7.943 nM] CB1 antagonist [pA2 for arachidonic acid release in CHO cells=9.9] with in vitro pharmacological characteristics similar to rimonabant including inverse agonism and brain penetrance.
-
In Vivo(±)-Ibipinabant ((±)-SLV319) (3 mg/kg) reduces unfasted glucose to a significantly greater degree than rimonabant at the same dose on days 17, 28 and 38. Chronic treatment with (±)-Ibipinabant ((±)-SLV319) significantly attenuates the progression of diabetes in ZDF rats, blunting the increase in blood glucose and HbA1c over time. Ibipinabant also reduces the hyperinsulinemia apparent at 6-8 weeks of age and attenuates the dramatic reduction in insulin levels observed 1-2 weeks later.
-
Synonyms(±)-SLV319 | (±)-BMS6462
-
PathwayOthers
-
TargetOther Targets
-
RecptorCB1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number362519-49-1
-
Formula Weight487.4
-
Molecular FormulaC23H20Cl2N4O2S
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 31 mg/mL; 63.60 mM
-
SMILESO=S(=O)(N=C(NC)N1CC(C(=N1)c2ccc(Cl)cc2)c3ccccc3)c4ccc(Cl)cc4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Chorvat RJ, et al.Bioorg Med Chem Lett. 2012 Oct 1;22(19):6173-80.
molnova catalog
related products
-
Dansyl chloride
Dansyl chloride reacts with primary amino groups in both aliphatic and aromatic amines to produce stable blue- or blue-green-fluorescent sulfonamide adducts. It is widely used to modify amino acids, specifically, protein sequencing and amino acid analysis.
-
Cromoglicic acid
Cromoglicic acid is a mast cell stabilizer with anti-inflammatory activity that prevents the release of inflammatory chemicals such as histamine, leukotrienes from mast cells.
-
2-APB
2-Aminoethoxydiphenyl borate (2-APB) is a chemical that acts to inhibit both IP3 receptors and TRP channels (although it activates TRPV1, TRPV2, & TRPV3 at higher concentrations).
